A threat to innovation?
Could recent legal decisions on Supplementary Protection Certificates (SPCs) prove to be a hammer blow for the pharma industry?
Read More
Search Results for: Joel Beevers
Narrowing the provision
The Court of Justice of the European Union (CJEU) has dealt a blow to innovators in two recent significant judgments, addressing questions posed by national courts struggling to judge the eligibility of SPC applications.
Read More- Nova’s Xromi approved in UK and EU for vaso-occlusive complications of SCD
- Study reveals vitamin D-altered mouse gut bacteria provides better cancer immunity
- Cambridge researchers use AI to accelerate drug design for Parkinson’s disease
- Study finds mechanical changes in tumour tissue offer new insights for cancer research
- Cambridge study finds AI more accurately assesses eye problems compared to doctors
